Gross cystic breast disease: Overview and directions for future research

M. J. Reed, A. Angeli, J. H. Thijssen, A. Milewicz, I. Számel, J. Huber, A. Harlozinska-Szmyrka, J. Tóth, J. Kornafel

Research output: Article

4 Citations (Scopus)

Abstract

As previously discussed, there is now a growing consensus that the presence of GCBD indicates an increased risk for breast cancer in later life. It is therefore important for the management of patients to determine whether the cyst is of the higher risk type (Type I). Further biochemical analysis of BCF is desirable to identify markers of cancer risk. By combining such biochemical studies with the long-term follow-up of patients with Type I cysts, valuable new information will be provided to assist in the future management of patients. The incidence of GCBD appears to be on the increase in some Eastern European countries. By carrying out long-term studies in such countries further insight into the aetiology of GCBD may be obtainable. In these countries, it should be possible to relate changes in the incidence of GCBD to changes in dietary habits, and thus provide important information as to the role of diet in the aetiology of this disease. The lack of effective therapy for GCBD indicates that there is an urgent need to carefully evaluate a number of potential therapeutic agents for use in treating this disease. Only by carrying out basic studies to determine the course of the disease, however, will it be possible to develop a rational form of therapy for this disease. The meeting in Wroclaw, Poland, concluded with the consensus that progress in understanding the development of GCBD, its relationship with breast cancer and the development of effective endocrine therapies would be greatly assisted by pursuing large-scale, multi-centre studies. Such collaborative research will enable the collection and characterisation of large numbers of BCF samples. The establishment of a BCF bank would help to rapidly evaluate the potential of any new markers of breast cancer risk which may be identified in BCF. Furthermore, such multi-centre studies should allow a number of new endocrine therapies for this disease to be quickly evaluated, using sufficient numbers of patients to determine the most effective form of therapy for this widespread disease.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalEndocrine-Related Cancer
Volume1
Issue number2
Publication statusPublished - 1994

Fingerprint

Fibrocystic Breast Disease
Breast Neoplasms
Cysts
Consensus
Endocrine System Diseases
Therapeutics
Incidence
Therapeutic Uses
Feeding Behavior
Poland
Direction compound
Diet
Research
Neoplasms

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism

Cite this

Reed, M. J., Angeli, A., Thijssen, J. H., Milewicz, A., Számel, I., Huber, J., ... Kornafel, J. (1994). Gross cystic breast disease: Overview and directions for future research. Endocrine-Related Cancer, 1(2), 9-13.

Gross cystic breast disease : Overview and directions for future research. / Reed, M. J.; Angeli, A.; Thijssen, J. H.; Milewicz, A.; Számel, I.; Huber, J.; Harlozinska-Szmyrka, A.; Tóth, J.; Kornafel, J.

In: Endocrine-Related Cancer, Vol. 1, No. 2, 1994, p. 9-13.

Research output: Article

Reed, MJ, Angeli, A, Thijssen, JH, Milewicz, A, Számel, I, Huber, J, Harlozinska-Szmyrka, A, Tóth, J & Kornafel, J 1994, 'Gross cystic breast disease: Overview and directions for future research', Endocrine-Related Cancer, vol. 1, no. 2, pp. 9-13.
Reed MJ, Angeli A, Thijssen JH, Milewicz A, Számel I, Huber J et al. Gross cystic breast disease: Overview and directions for future research. Endocrine-Related Cancer. 1994;1(2):9-13.
Reed, M. J. ; Angeli, A. ; Thijssen, J. H. ; Milewicz, A. ; Számel, I. ; Huber, J. ; Harlozinska-Szmyrka, A. ; Tóth, J. ; Kornafel, J. / Gross cystic breast disease : Overview and directions for future research. In: Endocrine-Related Cancer. 1994 ; Vol. 1, No. 2. pp. 9-13.
@article{c9e87522b55343adaf701fb0e32c086a,
title = "Gross cystic breast disease: Overview and directions for future research",
abstract = "As previously discussed, there is now a growing consensus that the presence of GCBD indicates an increased risk for breast cancer in later life. It is therefore important for the management of patients to determine whether the cyst is of the higher risk type (Type I). Further biochemical analysis of BCF is desirable to identify markers of cancer risk. By combining such biochemical studies with the long-term follow-up of patients with Type I cysts, valuable new information will be provided to assist in the future management of patients. The incidence of GCBD appears to be on the increase in some Eastern European countries. By carrying out long-term studies in such countries further insight into the aetiology of GCBD may be obtainable. In these countries, it should be possible to relate changes in the incidence of GCBD to changes in dietary habits, and thus provide important information as to the role of diet in the aetiology of this disease. The lack of effective therapy for GCBD indicates that there is an urgent need to carefully evaluate a number of potential therapeutic agents for use in treating this disease. Only by carrying out basic studies to determine the course of the disease, however, will it be possible to develop a rational form of therapy for this disease. The meeting in Wroclaw, Poland, concluded with the consensus that progress in understanding the development of GCBD, its relationship with breast cancer and the development of effective endocrine therapies would be greatly assisted by pursuing large-scale, multi-centre studies. Such collaborative research will enable the collection and characterisation of large numbers of BCF samples. The establishment of a BCF bank would help to rapidly evaluate the potential of any new markers of breast cancer risk which may be identified in BCF. Furthermore, such multi-centre studies should allow a number of new endocrine therapies for this disease to be quickly evaluated, using sufficient numbers of patients to determine the most effective form of therapy for this widespread disease.",
author = "Reed, {M. J.} and A. Angeli and Thijssen, {J. H.} and A. Milewicz and I. Sz{\'a}mel and J. Huber and A. Harlozinska-Szmyrka and J. T{\'o}th and J. Kornafel",
year = "1994",
language = "English",
volume = "1",
pages = "9--13",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "2",

}

TY - JOUR

T1 - Gross cystic breast disease

T2 - Overview and directions for future research

AU - Reed, M. J.

AU - Angeli, A.

AU - Thijssen, J. H.

AU - Milewicz, A.

AU - Számel, I.

AU - Huber, J.

AU - Harlozinska-Szmyrka, A.

AU - Tóth, J.

AU - Kornafel, J.

PY - 1994

Y1 - 1994

N2 - As previously discussed, there is now a growing consensus that the presence of GCBD indicates an increased risk for breast cancer in later life. It is therefore important for the management of patients to determine whether the cyst is of the higher risk type (Type I). Further biochemical analysis of BCF is desirable to identify markers of cancer risk. By combining such biochemical studies with the long-term follow-up of patients with Type I cysts, valuable new information will be provided to assist in the future management of patients. The incidence of GCBD appears to be on the increase in some Eastern European countries. By carrying out long-term studies in such countries further insight into the aetiology of GCBD may be obtainable. In these countries, it should be possible to relate changes in the incidence of GCBD to changes in dietary habits, and thus provide important information as to the role of diet in the aetiology of this disease. The lack of effective therapy for GCBD indicates that there is an urgent need to carefully evaluate a number of potential therapeutic agents for use in treating this disease. Only by carrying out basic studies to determine the course of the disease, however, will it be possible to develop a rational form of therapy for this disease. The meeting in Wroclaw, Poland, concluded with the consensus that progress in understanding the development of GCBD, its relationship with breast cancer and the development of effective endocrine therapies would be greatly assisted by pursuing large-scale, multi-centre studies. Such collaborative research will enable the collection and characterisation of large numbers of BCF samples. The establishment of a BCF bank would help to rapidly evaluate the potential of any new markers of breast cancer risk which may be identified in BCF. Furthermore, such multi-centre studies should allow a number of new endocrine therapies for this disease to be quickly evaluated, using sufficient numbers of patients to determine the most effective form of therapy for this widespread disease.

AB - As previously discussed, there is now a growing consensus that the presence of GCBD indicates an increased risk for breast cancer in later life. It is therefore important for the management of patients to determine whether the cyst is of the higher risk type (Type I). Further biochemical analysis of BCF is desirable to identify markers of cancer risk. By combining such biochemical studies with the long-term follow-up of patients with Type I cysts, valuable new information will be provided to assist in the future management of patients. The incidence of GCBD appears to be on the increase in some Eastern European countries. By carrying out long-term studies in such countries further insight into the aetiology of GCBD may be obtainable. In these countries, it should be possible to relate changes in the incidence of GCBD to changes in dietary habits, and thus provide important information as to the role of diet in the aetiology of this disease. The lack of effective therapy for GCBD indicates that there is an urgent need to carefully evaluate a number of potential therapeutic agents for use in treating this disease. Only by carrying out basic studies to determine the course of the disease, however, will it be possible to develop a rational form of therapy for this disease. The meeting in Wroclaw, Poland, concluded with the consensus that progress in understanding the development of GCBD, its relationship with breast cancer and the development of effective endocrine therapies would be greatly assisted by pursuing large-scale, multi-centre studies. Such collaborative research will enable the collection and characterisation of large numbers of BCF samples. The establishment of a BCF bank would help to rapidly evaluate the potential of any new markers of breast cancer risk which may be identified in BCF. Furthermore, such multi-centre studies should allow a number of new endocrine therapies for this disease to be quickly evaluated, using sufficient numbers of patients to determine the most effective form of therapy for this widespread disease.

UR - http://www.scopus.com/inward/record.url?scp=0028085394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028085394&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028085394

VL - 1

SP - 9

EP - 13

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 2

ER -